CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab - Niehr, Franziska; Weichert, Wilko; Stenzinger, Albrecht (BioMed Central, 2015)